secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001558370-23-014403
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023
------------------------------------------------------------------------

- Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.
- Cash and equivalents $27.7M; management expects runway into Q4 2024.
- R&D expenses down to $2.2M from $6.8M; G&A down to $1.7M from $15.6M YoY.
- ATRN-119 Phase 1/2a enrollment ongoing; initial safety and PK data expected Q4 2023.
- Gabriela Gruia, M.D., appointed to Board of Directors; over 25 years clinical and regulatory experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/0001558370-23-014403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023014403/apre-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer